Study S001667

A Phase 2, Open-label, Randomised, Dose-Finding Study of XW003, Once-Weekly Human Glucagon-Like Peptide 1 Analogue, Compared With Once-Daily Liraglutide 3 mg in Adult Participants With Obesity

ClinicalTrials.gov record

Registration

Registration: NCT05111912
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE2
Masking: NONE
Status: COMPLETED
Enrollment: 206
Start: 2021-11-30
Primary completion: 2022-11-16
Lead sponsor: Sciwind Biosciences APAC CO Pty. Ltd.
Conditions: Obesity
Interventions: DRUG:XW003; DRUG:Saxenda
Results posted: FALSE
Individual participant data sharing: NO

Registered primary outcomes

Percentage change in participants body weight (%) from the Baseline [Week 26]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.